A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

Published: The New England Journal of Medicine
Date:
Authors: Aaron S Kelly 1 , Pernille Auerbach 1 , Margarita Barrientos-Perez 1 , Inge Gies 1 , Paula M Hale 1 , Claude Marcus 1 , Lucy D Mastrandrea 1 , Nandana Prabhu 1 , Silva Arslanian 1 , NN8022-4180 Trial Investigators
Abstract:
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight

Published: Diabetes Care
Date:
Authors: William I Sivitz 1 , Lawrence S Phillips 2 3 , Deborah J Wexler 4 , Stephen P Fortmann 5 , Anne W Camp 6 , Margaret Tiktin 7 , Magalys Perez 6 , Jacqueline Craig 8 , Priscilla A Hollander 9 , Andrea Cherrington 10 , Vanita R Aroda 11 , Meng Hee Tan 12 , Jonathan Krakoff 13 , Neda Rasouli 14 , Nicole M Butera 15 , Naji Younes 15 , GRADE Research Group
Abstract:
We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes.

Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Published: Diabetes Care
Date:
Authors: Deborah J Wexler 1 , Heidi Krause-Steinrauf 2 , Jill P Crandall 3 , Hermes J Florez 4 , Sophia H Hox 5 , Alexander Kuhn 6 , Ajay Sood 7 , Chantal Underkofler 8 , Vanita R Aroda 6 , GRADE Research Group
Abstract:
GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) is a 36-center unmasked, parallel treatment group, randomized controlled trial evaluating four diabetes medications added to metformin in people with type 2 diabetes (T2DM).

APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS

Published: Endocrine Practice
Date:
Authors: Ramfis Nieto-Martínez, Juan P González-Rivas, Eunice Ugel, Imperia Brajkovich, Alejandro Risquez, W Timothy Garvey, Jeffrey I Mechanick
Abstract:
To determine the prevalence of obesity according to the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) framework based on a complications-centric model with further application of the Cardiometabolic Disease Staging (CMDS) system in a Venezuelan population.

Diabetes Care in Venezuela

Published: Annals of Global Health
Date:
Authors: Ramfis Nieto-Martínez 1 , Juan P González-Rivas 2 , Marcos Lima-Martínez 3 , Victoria Stepenka 4 , Alejandro Rísquez 5 , Jeffrey I Mechanick 6
Abstract:
The incidence of type 2 diabetes (T2D) and its economic burden have increased in Venezuela, posing difficult challenges in a country already in great turmoil.

Transcultural diabetes nutrition algorithm (tDNA): Venezuelan application

Published: Nutrients
Date:
Authors: Ramfis Nieto-Martínez 1 , Osama Hamdy 2 , Daniel Marante 3 , María Inés Marulanda 4 , Albert Marchetti 5 , Refaat A Hegazi 6 , Jeffrey I Mechanick 7
Abstract:
Medical nutrition therapy (MNT) is a necessary component of comprehensive type 2 diabetes (T2D) management, but optimal outcomes require culturally-sensitive implementation.

Metabolic syndrome: from global epidemiology to individualized medicine

Published: Clinical Pharmacology & Therapeutics
Date:
Authors: J A Batsis 1 , R E Nieto-Martinez, F Lopez-Jimenez
Abstract:
The metabolic syndrome (MetS) encompasses a constellation of metabolic abnormalities that are thought to place patients at higher risk for the development of diabetes and cardiovascular (CV) disease.

Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes

Published: The Journal of Clinical Pharmacology
Date:
Authors: Michael L Christensen 1 , Bernd Meibohm, Edmund V Capparelli, Pedro Velasquez-Mieyer, George A Burghen, William V Tamborlane
Abstract:
This study assessed the single- and multiple-dose pharmacokinetics of 3 doses (15 mg, 30 mg, and 45 mg) of pioglitazone in 36 adolescents with type 2 diabetes.